BioCryst Pharmaceuticals (BCRX)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
At a market value of $2.0B, BioCryst Pharmaceuticals's free cash flow of $345M (fiscal 2025) would need to grow about -12% a year for the stock to be worth today's price.
Assumes a 9% discount rate and 3% growth after year 10, on free cash flow (operating cash flow minus capital spending) from BioCryst Pharmaceuticals's SEC filings. Change any assumption, or model revenue and margins instead, in the Modeling tab, or try your own numbers in the reverse DCF calculator.
Fundamental grade
Five factors scored 1 to 9 from BCRX's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from BioCryst Pharmaceuticals's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $157M | $271M | $331M | $451M | $875M |
| Net income | -$184M | -$247M | -$227M | -$89M | $264M |
| Free cash flow | -$145M | -$163M | -$97M | -$53M | $345M |
| EPS (diluted) | -$1.03 | -$1.33 | -$1.18 | -$0.43 | $1.21 |
| Operating margin | -113.1% | -54.8% | -31.3% | -0.56% | 39.0% |
Where the revenue comes from
Revenue by products, fiscal 2025. Every breakdown, year by year.
Superinvestors who own BCRX
From each investor's latest 13F filing (what a 13F shows). 2 of the investors we track hold it.
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| Cliff Asness AQR Capital Management |
Added | $22M | 0.01% | Q2 2026 |
| Joel Greenblatt Gotham Asset Management |
Trimmed | $2M | 0.00% | Q2 2026 |
Insider buying
Open-market purchases by BioCryst Pharmaceuticals's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Nov 13, 2025 | Gilbert Ray Cisneros, Jr. |
0 | $6.90 | — |
| Nov 13, 2025 | Gilbert Ray Cisneros, Jr. |
0 | $6.90 | — |
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when BCRX trades at or below it.
New accounts get 7 days of Pro, price alerts included. No card needed.
In the full deep dive
Questions
What growth does BioCryst Pharmaceuticals's stock price imply?
At a market value of $2.0B, BioCryst Pharmaceuticals would need its free cash flow to grow about -12% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price.
Are BioCryst Pharmaceuticals insiders buying the stock?
2 open-market insider purchases of BCRX in the last 12 months, from SEC Form 4 filings.
Which superinvestors own BioCryst Pharmaceuticals?
2 of the superinvestors Investingly tracks hold BCRX in their latest 13F, including Cliff Asness, Joel Greenblatt.
Companies like BioCryst Pharmaceuticals
All Healthcare stocks · Drug Manufacturers - Specialty & Generic stocks · Stock lists
Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.